Baxalta

Roche scores—again—in hemophilia drug patent case against Takeda
Roche scores—again—in hemophilia drug patent case against Takeda
Fierce Pharma
Roche
Takeda
patents
legal
Genentech
Baxalta
hemophilia
Flag link:
Takeda's Baxalta settles with Bayer over $173M hemophilia patent infringement verdict
Takeda's Baxalta settles with Bayer over $173M hemophilia patent infringement verdict
Fierce Pharma
Baxalta
Takeda
hemophilia
patents
Bayer
Adynovate
Flag link:
Takeda's Hemophilia A Drug: New Data and a $155 Million Patent Infringement Settlement
Takeda's Hemophilia A Drug: New Data and a $155 Million Patent Infringement Settlement
BioSpace
Takeda
clinical trials
Adynovate
Baxalta
Bayer
patents
Flag link:
Analyzing the orphan drugs market ($127bn)
Analyzing the orphan drugs market ($127bn)
GoinPharma
orphan drugs
Shire
Baxalta
Sanofi
Bioverativ
M&A
Flag link:
Why big pharma companies always create new spinoffs
Why big pharma companies always create new spinoffs
GoinPharma
spinoffs
Sanofi
Celgene
Biogen
AbbVie
Abbott Labs
Baxalta
Shire
Flag link:
Shire defends record as UBS cuts price target on staff satisfaction reviews
Shire defends record as UBS cuts price target on staff satisfaction reviews
Reuters
Shire
employees
Baxalta
Flag link:
Shire conservative as it navigates Baxalta integration
Shire conservative as it navigates Baxalta integration
BioPharma Dive
Shire Pharmaceuticals
Baxalta
M&A
Flag link:
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
Fierce Pharma
M&A
Stada
Shire
Baxalta
JNJ
Actelion
Mylan Labs
Pfizer
Takeda
Ariad Pharmaceuticals
Medivation
Flag link:
Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO
Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO
TheStreet.com
Alexion Pharma
Pharma CEOs
Ludwig Hantson
Baxalta
Flag link:
2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
Endpoints
M&A
Shire
Baxalta
Pfizer
Medivation
Mylan
Meda
AbbVie
Stemcentrx
Anacor
Flag link:
Baxalta pushes Shire to record revenues
Baxalta pushes Shire to record revenues
BioPharma Dive
Shire
Baxalta
earnings
Flag link:
Shire's new Baxalta hemophilia meds drop the ball in first combined quarter
Shire's new Baxalta hemophilia meds drop the ball in first combined quarter
Fierce Pharma
Shire
Baxalta
hemophilia
earnings
Flag link:
Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal
Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal
Endpoints
Shire
myelofibrosis
CTI BioPharma
Baxalta
M&A
pacritinib
Flag link:
AbbVie Is Under Duress With Fierce Competition
AbbVie Is Under Duress With Fierce Competition
Seeking Alpha
AbbVie
Humira
biosimilars
Amgen
Baxalta
Shire
Flag link:
Shire wants out of that $172M Baxalta deal with CTI Bio
Shire wants out of that $172M Baxalta deal with CTI Bio
Endpoints
Shire
Baxalta
CTI BioPharma
M&A
Flag link:
Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark
Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark
Fierce Biotech
Shire
Baxalta
hemophilia B
gene therapy
BAX 335
Spark Therapeutics
uniQure
Flag link:
Shire upgrades Baxalta cost savings after Q2 earnings beat
Shire upgrades Baxalta cost savings after Q2 earnings beat
Yahoo/Reuters
Shire
Baxalta
earnings
Flag link:
Shire bags a quick thumbs up for its newly won cancer drug pipeline
Shire bags a quick thumbs up for its newly won cancer drug pipeline
Endpoints
Shire
Baxalta
M&A
Onivyde
Flag link:
Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta
Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta
TheStreet.com
Shire
ADHD
Baxalta
Brexit
M&A
Vyvanse
Flag link:
Shire completes Baxalta acquisition
Shire completes Baxalta acquisition
Bizjournals.com
Shire
Baxalta
M&A
Flag link:

Pages